PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING...

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacological Treatments

Background:

• Symptomatic vitreomacular adhesion/traction (VMA/VMT) can impair visual function.
• Patient-reported outcomes are crucial for evaluating treatment efficacy in retinal conditions.
• The National Eye Institute Visual Function Questionnaire (VFQ-25) assesses patient-perceived visual functioning.

Purpose of the Study:

• To evaluate patient-reported visual function using the VFQ-25 after ocriplasmin treatment.
• To assess visual function in patients with symptomatic VMA/VMT, including those with macular holes.
• To compare visual function outcomes between ocriplasmin and sham treatment groups.

Main Methods:

• A prespecified secondary analysis of the OASIS trial data was conducted.
• Patients received either a single intravitreal injection of ocriplasmin (0.125 mg) or a sham injection.
• The VFQ-25 was administered at baseline and at 6, 12, and 24 months post-injection.

Main Results:

• At 24 months, 51.4% of patients receiving ocriplasmin showed a clinically meaningful (≥5-point) improvement in VFQ-25 composite scores, versus 30.1% in the sham group (P=0.003).
• The incidence of ≥5-point worsening in VFQ-25 composite scores was lower in the ocriplasmin group (9.5%) compared to the sham group (15.6%) at 24 months.
• Improvements in VFQ-25 scores were observed more frequently with ocriplasmin treatment, irrespective of baseline macular hole status.

Conclusions:

• Ocriplasmin treatment resulted in a higher percentage of patients reporting clinically meaningful improvements in self-assessed visual function compared to sham.
• These findings highlight the positive impact of ocriplasmin on patient-reported visual function in VMA/VMT.
• The VFQ-25 is a valuable tool for assessing treatment benefits in patients with VMA/VMT.